1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development

BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection and hospitalization in infants. MK-1654 is a monoclonal antibody (mAb) being developed to prevent RSV infection in infants and is undergoing evaluation in a Phase 1 study. Incorporation of YTE...

Descripción completa

Detalles Bibliográficos
Autores principales: Maas, Brian, Aliprantis, Antonios, Wolford, Dennis, Fayad, Ghassan, Vora, Kalpit, Geng, Dong, Ma, Hua, Caro, Luzelena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252424/
http://dx.doi.org/10.1093/ofid/ofy210.1215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252424/
http://dx.doi.org/10.1093/ofid/ofy210.1215

Ejemplares similares